Betmiga Use In Pregnancy & Lactation

Pregnancy: There are limited amount of data from the use of Mirabegron (Betmiga) in pregnant women. Studies in animals have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). Mirabegron (Betmiga) is not recommended during pregnancy and in women of childbearing potential not using contraception.
Breast-feeding: Mirabegron (Betmiga) is excreted in the milk of rodents and therefore is predicted to be present in human milk (see Pharmacology: Toxicology: Preclinical safety data under Actions). No studies have been conducted to assess the impact of mirabegron on milk production in humans, its presence in human breast milk, or its effects on the breast-fed child.
Mirabegron (Betmiga) should not be administered during breast-feeding.
Fertility: There were no treatment-related effects of Mirabegron (Betmiga) on fertility in animals (see Pharmacology: Toxicology: Preclinical safety data under Actions). The effect of mirabegron on human fertility has not been established.